Clinical trials: Advanced Gynecological Cancers, open to volunteers
Gynecological Tumors
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of…
- Trial name
- NCT06798207
- Testing
- TQB2102 for injection
- Where
- 31 sites in China
- Volunteers
- 170 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies
SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies
This is a prospective, open-label, multicenter, single-arm Phase II study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT/SKB264) in combination with tagitanlimab (KL-A167) as second-line or later…
- Trial name
- NCT07738757
- Testing
- Sacituzumab Tirumotecan (Sac-TMT), Tagitanlimab
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Carcinoma, Cervical Carcinoma
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
Multicenter ambispective observational study (prospective/retrospective)
- Conditions
- Ovarian Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Vulvar Carcinoma
- Trial name
- NCT07267780
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute, Naples
Ovarian Cancer, Fallopian Tube Cancer
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
- Trial name
- NCT06906341
- Testing
- Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
- Where
- 49 sites in United States, Belgium and 6 more
- Volunteers
- 270 people
- Sponsor
- Corcept Therapeutics
Gynecologic Cancer, Immunotherapy
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation.
- Conditions
- Gynecologic Cancer, Immunotherapy, Gut Microbiome
- Trial name
- NCT04957511
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Viome
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
Gynecological Solid Tumors
A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors
Screening patients who meet the criteria for peripheral blood mononuclear cell (PBMC) isolation and cell preparation. Based on the status of cell preparation and mutual agreement between the researcher and the participant, the…
- Trial name
- NCT06904131
- Testing
- Cell therapy with bispecific antibodies
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Tumours, Gynecological
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns.
- Trial name
- NCT06796907
- Testing
- Mo-Rez, Dostarlimab, Bevacizumab
- Where
- 82 sites in United States, Argentina and 21 more
- Volunteers
- 305 people
- Sponsor
- GlaxoSmithKline
Gynecological Cancers
Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers
This is an open-label, first-in-human, dose escalation study evaluating investigational drug PORPHYSOSMES (PS, pegylated porphyrin-lipid conjugate-containing nanoparticle suspension) and 64Cu-PORPHYSOMES (64Cu-PS, pegylated…
- Trial name
- NCT06977126
- Testing
- PORPHYSOMES, 64Cu-PORPHYSOMES
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Gynecological Malignancies
9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.
- Trial name
- NCT06926998
- Testing
- 9MW2821+other anticancer therapy
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Cervical Cancer, Ovarian Cancer
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or…
- Trial name
- NCT06769152
- Testing
- HLX43
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer, Lung Cancer
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma
- Trial name
- OCTANE (NCT02906943)
- Where
- 7 sites in Canada
- Volunteers
- 10,000 people
- Sponsor
- University Health Network, Toronto
Gynecologic Cancer, Radiotherapy Side Effect
Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)
This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy…
- Conditions
- Gynecologic Cancer, Radiotherapy Side Effect, Radiotherapy; Complications, Survivorship
- Trial name
- GYN-ART (NCT06306170)
- Testing
- Image Guided Radiotherapy
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS San Raffaele
Advanced Gynecological Cancers
Exploratory Clinical Study of cCTL in Combination With Immunotherapy for Advanced Gynecologic Malignancies
This study is a single-arm, open-label, interventional, and exploratory clinical trial,the goal of which is to evaluate the safety and clinical efficacy of the novel tumor-specific cytotoxic T lymphocyte (cCTL) injection in…
- Trial name
- NCT07434284
- Testing
- cCTL treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Advanced Gynecological Malignancies
Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies
This study is a single-arm, open-label, multicenter Phase IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of BRY812 for Injection in patients with LIV-1-positive advanced gynecological…
- Trial name
- NCT07311538
- Testing
- BRY812 for injection
- Volunteers
- 56 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Advanced Gynecologic Malignancies
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Advanced Gynecological Tumors.
This is a multicenter, open-label, phase II clinical study to evaluate the safety and preliminary efficacy of RNK08954 in patients with advanced gynecological tumors
- Trial name
- NCT07848893
- Testing
- RNK08954
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ranok Therapuetics Co. Ltd.
Advanced Gynecological Malignancies
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
This is an open-label, multicenter, Phase II clinical study to evaluate the efficacy and safety of SKB518 as monotherapy or combination therapy in patients with advanced gynecological malignancies.
- Trial name
- NCT07448922
- Testing
- SKB518 for injection, Carboplatin (AUC 5), Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 280 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Gynecological Malignancies, Solid Tumors
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors
This study is a single-arm, open-label, multicenter, non-randomized phase II clinical study evaluating the efficacy and safety of BL-M09D1 for injection in patients with locally advanced or metastatic gynecological malignancies…
- Trial name
- NCT07769229
- Testing
- BL-M09D1
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Gynecological Malignancy
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.
- Trial name
- NCT06654440
- Testing
- SHR-A2102 for injection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.